大分割放射外科联合贝伐珠单抗治疗既往高剂量照射后局部复发性脑转移
本研究纳入24例既往接受过照射的复发性脑转移患者,采用CyberKnife大分割立体定向放射外科(FSRS)9.5-29 Gy(2-5次)联合贝伐珠单抗4周期(5 mg/kg,每3周一次)作为挽救治疗。
要点
- FSRS联合贝伐珠单抗可作为既往高剂量照射后局部复发脑转移的挽救方案
- 挽救治疗后1年总生存率87.5%,1/2级乏力见于8例(33%)
核心结论
- FSRS联合辅助贝伐珠单抗作为挽救治疗方案显示出良好的临床和影像学控制。
- 挽救FSRS后放射性坏死与局部复发的鉴别诊断有待进一步研究。
研究设计与样本
- 挽救FSRS剂量9.5-29 Gy,分2-5次,等剂量线62%-75%,采用CyberKnife,剂量依据脑肿瘤体积、部位和既往剂量确定。
- 贝伐珠单抗共4周期,5 mg/kg,每3周一次。
- 主要终点为挽救治疗后的总生存,次要终点包括临床反应(Karnofsky功能状态评分)、影像学反应(磁共振成像)和治疗相关不良事件。
主要发现
- 挽救性立体定向放射外科后1年总生存率为87.5%。
- 临床功能显著改善(最佳Karnofsky功能状态评分,P<0.05,配对t检验)。
- 1/2级乏力见于8例(33%)患者,3级乏力和头痛各见1例。
临床怎么用
- 对既往高剂量照射后局部复发脑转移患者,可考虑FSRS联合贝伐珠单抗作为挽救治疗。
- 治疗期间需关注乏力、头痛等不良事件,并注意与放射性坏死鉴别。
局限性
- 研究为单中心、小样本(24例)研究。
- 原文未报告对照设计及随访时长等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selection of appropriate treatment for patients with recurrent brain metastasis (BM) remains uncertain. Recent studies have demonstrated a significant response rate and acceptable toxicity using fractionated stereotactic radiosurgery (FSRS) in patients with locally recurrent large BM. The aim of this study was to evaluate efficacy and toxicity of FSRS with bevacizumab as a new salvage treatment for locally recurrent BM with previous high-dose irradiation. METHODS: Patients with recurrent BM previously irradiated were enrolled. Salvage FSRS dose was 9.5-29 Gy (2-5 fractions) with 62%-75% isodose line by CyberKnife according to the brain tumor volume, site, and previous dose. Bevacizumab was prescribed for 4 cycles (5 mg/kg, every 3 weeks). The primary objective was to identify the overall survival after salvage treatment. Secondary objectives included clinical response (Karnofsky performance scale), imaging response (magnetic resonance imaging) and treatment-related adverse events. RESULTS: From December 2009 to October 2016, 24 patients were enrolled. The 1-year overall survival after salvage stereotactic radiosurgery was 87.5%. Twenty-three (96%) patients had a positive imaging response with a T2 volume reduction range of 6-22 cm3 (median 14 cm3, P = 0.032, paired t test). Significant clinical improvement was achieved (best Karnofsky performance scale score, P < 0.05, paired t test). Grade 1/2 fatigue was observed in 8 (33%) patients. Grade 3 fatigue and headache occurred in 1 patient. CONCLUSIONS: FSRS with adjuvant bevacizumab treatment showed favorable clinical and radiologic control as a salvage treatment regimen. The diagnoses of radiation necrosis and local recurrence after salvage FSRS warrant further study.
引用
- Guan Y, Wang C, Zhu H, et al. Hypofractionated Radiosurgery Plus Bevacizumab for Locally Recurrent Brain Metastasis with Previously High-Dose Irradiation. World Neurosurg. 2019. PMID: 31505283. doi:10.1016/j.wneu.2019.08.233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。